Companies like Biocure Technology, Inc. (CSE:CURE), Premiere Health Group, Inc. (CSE:PHGI), and Aurinia Pharmaceuticals, Inc. (TSX:AUP) manage to stay strong on the stock market despite the poor trends in other sectors. Here’s why these brands continue to draw in investors despite the unsteady stock market.
Biocure Technology, Inc.
Trading at around $0.51 on the Canadian Securities Exchange (CSE), Biocure Technology is one of the most consistent movers in the healthcare industry. It traded at $1.64 earlier this year and investors are hoping that it will be able to bounce back soon. Based on recent developments in the company, that may very well be possible.
The company’s primary offering is its line of in-situ polymerizing hydrogels and block copolymers. To help improve its products, the company recently entered into a land purchase agreement with Korea Land & Housing Corp. to secure a 6,060-square-meter industrial usage parcel. This will be used to expand the company’s manufacturing facilities thus increasing its R&D and production capacity.
Premiere Health Group. Inc
Premier Health Group is currently trading at $0.73 at the CSE. It came in 2018 trading at $1.15 but it hit a rough patch around April when its price dropped to a low of $0.05. However, that hurdle has been surpassed already and movement has been great since October.
The company is deep into the development of healthcare technologies. However, ever since Canada opened its doors to recreational marijuana, the brand began opening opportunities to it as well. The company recently announced that it talked with licensed producers in Canada to help with its plans to include cannabis in its clinics. It is also working with physicians to provide its patients with all the cannabis information they need to know.
Aurinia Pharmaceuticals, Inc.
Aurinia Pharmaceuticals, Inc. is trading heavily at the Toronto Stock Exchange (TSX) at a price of $7.25 per share. It has been playing around the $6 to $8 range this year. The company also has a massive market cap of $618 million, enticing even more investors to buy in while the price is relatively low.
As one of the more prominent figures in Canada’s biotechnology industry, Aurinia Pharmaceuticals’ potential for growth remains relatively high. The company focuses heavily on creating and supporting technologies that will be able to help outpatients with debilitating diseases. The reason why investors are so drawn into it is that they are waiting for Aurinia Pharmaceuticals to create a healthcare technology unlike any other.
Various sectors on the stock market have been struggling in the past months but movement in Canada’s healthcare industry remain somewhat positive. Many investors are still optimistic about the growth of the nation’s healthcare sector as evident by the rallying of a few stocks this month, and their positive trend could pour over next year.